Home > Journals > Minerva Pediatrics > Past Issues > Articles online first > Minerva Pediatrics 2021 Apr 12

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

 

Minerva Pediatrics 2021 Apr 12

DOI: 10.23736/S2724-5276.21.06099-0

Copyright © 2021 EDIZIONI MINERVA MEDICA

language: English

Mucosal healing is not associated with better outcome during 7 years of follow-up in pediatric patients with Crohn’s disease

Jan MELEK 1 , Markéta ŠTANCLOVÁ 1, Petr DĚDEK 1, Radek ŠTICHHAUER 2, Jaroslav KOUDELKA 2, Tomáš DOUDA 3, Ilja TACHECÍ 3, Ladislav DOUDA 3, Tomáš VAŇÁSEK 4, Jan BUREŠ 3

1 Department of Pediatrics, Faculty of Medicine in Hradec Králové, University Hospital Hradec Králové, Charles University in Prague, Hradec Králové, Czech Republic; 2 Department of Pediatric Surgery and Traumatology, University Hospital in Hradec Kralove, Hradec Králové, Czech Republic; 3 2nd Department of Internal Medicine - Gastroenterology, University Hospital in Hradec Kralove, Hradec Králové, Czech Republic; 4 Hepato-Gastroenterologie HK, s.r.o, Hradec Králové, Czech Republic



BACKGROUND: Mucosal healing (MH) has become a perspective treatment target in patients with Crohn’s disease (CD). Data about the impact of MH on long-term outcome in pediatric patients are still scarce.
METHODS: 76 pediatric patients with CD were evaluated retrospectively (2000-2015) in a tertiary care center. Based on MH achievement, they were divided into two groups (MH, n= 17; and No MH, n=59). The primary endpoint was to assess the association of MH and the need for CD-related hospitalizations or surgery in pediatric patients with CD.
RESULTS: The number of hospitalized patients was 24% in the MH group and 42% in the No MH group, P = 0.26. The total number of CD-related hospitalizations was not significant between the MH group and the No MH group (5 vs. 41, P = 0.15). The time to the first hospitalization was 24 months in MH and 21 months in No MH, P>0.99. 24% patients in the MH group and 39% patients in the No MH group underwent CD-related operation, P = 0.39. Time to the first operation was 43 months for MH and 19 months for the No MH group, P = 0.13. The follow-up period was 91 months in the MH group and 80 months in the No MH group, P = 0.74. The use of infliximab was positively associated with MH, P = 0.002.
CONCLUSIONS: MH was not associated with fewer CD-related hospitalizations or operations in pediatric patients with CD during seven years of follow-up.


KEY WORDS: Hospitalization; Long-term outcome; Mucosal healing; Operation; Pediatric Crohn’s disease

top of page